Does Blue Cross Blue Shield of Alabama Cover Jardiance?

How BCBS of Alabama Formularies Handle Jardiance

Blue Cross Blue Shield of Alabama maintains separate formularies for its commercial (employer-sponsored and individual marketplace) plans and its Medicare Advantage plans. Jardiance appears on both, but the tier placement, copay structure, and utilization management requirements differ between plan types.

Commercial Plan Formulary Placement

On most BCBSAL commercial formularies, Jardiance sits on Tier 2 (preferred brand) or Tier 3 (non-preferred brand). Tier 2 placement typically means a copay between $35 and $75 per month. Tier 3 placement pushes that range to $75 to $150, or a coinsurance percentage of 25% to 40% of the negotiated drug cost. Your Summary of Benefits and Coverage (SBC) document or the BCBSAL member portal will confirm your plan's exact tier.

Medicare Advantage Formulary Placement

BCBSAL Medicare Advantage (Part D) plans also cover Jardiance, but these plans frequently place SGLT2 inhibitors on Tier 3 or a specialty tier. Medicare beneficiaries may face coinsurance of 25% to 33% during the initial coverage phase. After reaching the coverage gap threshold ($5,630 in 2026), the Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drugs applies, which can significantly reduce total yearly spending on Jardiance 1.

Checking Your Specific Plan

The fastest way to confirm coverage is to log in to the BCBSAL member portal and search the formulary tool by entering "empagliflozin" or "Jardiance." You can also call the number on the back of your insurance card and ask the representative to verify tier placement, prior authorization status, and any step therapy requirements for your plan.

Prior Authorization and Step Therapy Requirements

BCBSAL frequently requires prior authorization (PA) before covering Jardiance. This means your prescribing clinician must submit documentation showing that the medication is medically necessary for your condition.

What Triggers Prior Authorization

PA is most commonly required when Jardiance is prescribed for type 2 diabetes management. BCBSAL typically asks for evidence that the patient has tried and failed (or has a contraindication to) metformin before approving an SGLT2 inhibitor. This step therapy protocol aligns with the American Diabetes Association's (ADA) Standards of Care, which recommend metformin as first-line pharmacotherapy for most adults with type 2 diabetes 2.

Heart Failure Indication and PA

For the heart failure indication, the PA process may differ. The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure gives SGLT2 inhibitors a Class I recommendation for patients with heart failure regardless of ejection fraction 3. When prescribed specifically for heart failure, BCBSAL may waive the metformin step therapy requirement. Your cardiologist or prescriber should note the heart failure diagnosis code (ICD-10 I50.x) on the PA form to expedite approval.

Typical PA Turnaround

Standard PA decisions from BCBSAL take 48 to 72 hours for commercial plans. Urgent requests can be processed within 24 hours. Medicare Advantage PA decisions follow CMS timelines: 72 hours standard, 24 hours expedited.

Why Jardiance Lands on Formularies: The Clinical Evidence

Insurers cover Jardiance because the clinical trial data supporting its use is extensive. Three landmark trials drive formulary inclusion decisions for empagliflozin.

EMPA-REG OUTCOME

The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin reduced cardiovascular death by 38% (HR 0.62, 95% CI 0.49-0.77, P<0.001) in adults with type 2 diabetes and established cardiovascular disease over a median follow-up of 3.1 years 4. This was the first SGLT2 inhibitor trial to show a mortality benefit, and it changed prescribing patterns globally.

EMPEROR-Reduced

In the EMPEROR-Reduced trial (N=3,730), empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure by 25% (HR 0.75, 95% CI 0.65-0.86, P<0.001) in patients with heart failure and reduced ejection fraction, regardless of diabetes status 5.

EMPEROR-Preserved

EMPEROR-Preserved (N=5,988) extended the benefit to heart failure with preserved ejection fraction, showing a 21% reduction in the composite of cardiovascular death or heart failure hospitalization (HR 0.79, 95% CI 0.69-0.90, P<0.001) 6. Dr. Milton Packer, one of the trial's co-principal investigators, stated: "EMPEROR-Preserved is the first trial to show a clear benefit of any drug in patients with heart failure with preserved ejection fraction."

These three trials collectively support FDA labeling that makes Jardiance one of the most broadly indicated SGLT2 inhibitors on the market.

What Jardiance Costs on a BCBS of Alabama Plan

The out-of-pocket cost for Jardiance varies widely based on plan type, tier, deductible status, and whether you use manufacturer savings programs.

Typical Cost Scenarios

A BCBSAL commercial PPO member with Jardiance on Tier 2 (preferred brand) and a $500 pharmacy deductible will pay full retail price (roughly $570 to $620) until the deductible is met, then a copay of $35 to $75 per fill. A member with Tier 3 placement and 30% coinsurance after deductible would pay approximately $170 to $185 per month.

For Medicare Advantage enrollees, the Inflation Reduction Act's $2,000 annual Part D out-of-pocket cap means that even at higher coinsurance rates, total yearly drug spending is capped. A beneficiary paying 25% coinsurance on Jardiance ($142 to $155/month) would hit the $2,000 cap within approximately 13 to 14 months, after which they pay $0 for covered Part D drugs for the remainder of the plan year.

How to Reduce Your Cost

Several strategies can lower out-of-pocket spending on Jardiance for BCBSAL members:

• Manufacturer copay card. Boehringer Ingelheim's Jardiance Savings Card can reduce commercial copays to as low as $10 per month for eligible patients. This card is not valid for government-insured beneficiaries (Medicare, Medicaid, Tricare) 7.
• Mail-order pharmacy. BCBSAL often provides a 90-day supply at a lower per-unit cost through its preferred mail-order pharmacy. Check whether your plan offers a 90-day option.
• Formulary exception request. If Jardiance is on Tier 3 but a clinically equivalent SGLT2 inhibitor is on Tier 2, your doctor can submit a formulary exception request arguing that Jardiance is medically necessary due to prior treatment failure or adverse effects with the Tier 2 alternative.
• Patient assistance programs. Boehringer Ingelheim's patient assistance program provides Jardiance at no cost to uninsured or underinsured patients who meet income eligibility criteria (generally household income at or below 400% of the federal poverty level).

Jardiance vs. Other Covered SGLT2 Inhibitors on BCBSAL

BCBSAL formularies typically include multiple SGLT2 inhibitors. Understanding their relative tier placement helps you and your prescriber select the most cost-effective option.

Formulary Comparison

Farxiga (dapagliflozin) is the most common SGLT2 alternative on BCBSAL formularies and is sometimes placed one tier lower than Jardiance, making it the preferred option. Both drugs share the same FDA-approved indications for type 2 diabetes and heart failure. In the DAPA-HF trial (N=4,744), dapagliflozin reduced the composite of cardiovascular death or worsening heart failure by 26% (HR 0.74, 95% CI 0.65-0.85, P<0.001) 8. The ADA Standards of Care do not recommend one SGLT2 inhibitor over another, noting that class-level cardiovascular and renal benefits are well established 2.

When Jardiance May Be Preferred

If your prescriber specifically wants empagliflozin based on the EMPA-REG OUTCOME data or because you tolerated it well previously, a PA or formulary exception can justify Jardiance even when Farxiga is the preferred formulary agent. Document the clinical rationale clearly. The ADA's 2024 Standards of Care note that "individualization of therapy based on patient-specific factors is recommended," which supports exception requests 2.

Filing an Appeal if BCBSAL Denies Coverage

Denials happen. BCBSAL may deny Jardiance coverage because step therapy was not completed, documentation was incomplete, or the plan excludes the drug for a specific indication. You have the right to appeal.

Internal Appeal Process

BCBSAL allows one level of internal appeal for commercial plans and two levels for Medicare Advantage plans. Your prescriber should submit a letter of medical necessity citing the relevant clinical trial data (EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved) and explaining why alternative therapies are not appropriate. Include lab values (HbA1c, eGFR, BNP if applicable), a list of prior medications tried, and the specific diagnosis codes.

External Review

If the internal appeal is denied, you can request an independent external review. For commercial plans governed by Alabama state law, the Alabama Department of Insurance oversees external reviews. For Medicare Advantage plans, the appeal moves through the CMS reconsideration and Administrative Law Judge process.

Turnaround Times

Internal appeals: 30 days for commercial standard requests, 72 hours for urgent. Medicare Advantage: 7 days for standard Part D appeals, 72 hours for expedited.

Monitoring and Safety Considerations While on Jardiance

Once your coverage is approved, ongoing monitoring ensures safe use of empagliflozin.

Baseline and Follow-Up Labs

Before starting Jardiance, your clinician should check renal function (eGFR, serum creatinine), fasting glucose or HbA1c, blood pressure, and a lipid panel. The ADA recommends reassessing HbA1c every 3 months until stable, then every 6 months 2. Renal function should be monitored at least annually, or more frequently in patients with eGFR 30 to 60 mL/min/1.73m².

Key Side Effects to Report

SGLT2 inhibitors carry FDA boxed warnings and labeled risks including genital mycotic infections (occurring in 5% to 10% of patients), urinary tract infections, volume depletion and hypotension, and rare cases of diabetic ketoacidosis (DKA), sometimes occurring at near-normal glucose levels (euglycemic DKA) 9. The FDA reported 73 cases of SGLT2-associated DKA between March 2013 and May 2015, prompting a safety communication 9. Patients should be counseled to hold Jardiance during periods of prolonged fasting, surgery, or acute illness.

Kidney Protection Data

Empagliflozin has demonstrated renal protective effects. In the EMPA-KIDNEY trial (N=6,609), empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72, 95% CI 0.64-0.82, P<0.001) in patients with chronic kidney disease, with or without diabetes 10. This trial expanded the labeled indication and may strengthen PA approval for patients with CKD.

How BCBSAL Coverage Compares to Other Alabama Insurers

BCBSAL holds the largest market share among health insurers in Alabama, covering approximately 87% of the commercially insured population in the state. Other insurers in Alabama, including UnitedHealthcare and Aetna, also cover Jardiance but tier placement and PA requirements vary.

Market Context

Because BCBSAL dominates the Alabama insurance market, its formulary decisions affect a disproportionately large number of patients. The 2024 ADA Standards of Care emphasize that "cost and access should be considered when selecting glucose-lowering therapies" 2. If BCBSAL places Jardiance on Tier 3 while Farxiga sits on Tier 2, many Alabama clinicians default to dapagliflozin for cost reasons unless a patient-specific factor favors empagliflozin.

Formulary Changes

BCBSAL updates its formularies at least annually, typically effective January 1. Mid-year formulary changes can occur but require 30-day advance notice to members on commercial plans. Check the BCBSAL formulary tool or call member services each January to confirm Jardiance's current tier and PA status for the new plan year.